Hanall Biopharma Co., Ltd. (KRX: 009420)
South Korea flag South Korea · Delayed Price · Currency is KRW
40,900
+400 (0.99%)
Nov 15, 2024, 3:30 PM KST

Hanall Biopharma Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Operating Revenue
130,374134,910109,995101,59488,602108,452
Upgrade
Other Revenue
-0-0-0-0--
Upgrade
Revenue
130,374134,910109,995101,59488,602108,452
Upgrade
Revenue Growth (YoY)
0.30%22.65%8.27%14.66%-18.30%18.09%
Upgrade
Cost of Revenue
63,74759,87048,12041,36438,02745,771
Upgrade
Gross Profit
66,62775,04061,87660,23150,57562,681
Upgrade
Selling, General & Admin
50,68947,52042,58638,47234,26434,114
Upgrade
Research & Development
21,89823,94516,49810,4629,31610,051
Upgrade
Other Operating Expenses
646.58669.45584.09605.75541.03605.07
Upgrade
Operating Expenses
74,04973,29660,37050,13244,64045,591
Upgrade
Operating Income
-7,4231,7431,50610,0995,93517,090
Upgrade
Interest Expense
-67.91-63.86-21.88-25.48-16.01-13.75
Upgrade
Interest & Investment Income
879.611,2271,427719.842,1452,142
Upgrade
Earnings From Equity Investments
-123.09-62.12-45.39---
Upgrade
Currency Exchange Gain (Loss)
-65.51349.6-600.15-115.9482.78281.27
Upgrade
Other Non Operating Income (Expenses)
-987.28-1,067-228.48-745.8711,138213.68
Upgrade
EBT Excluding Unusual Items
-7,7872,1272,0379,93219,28419,713
Upgrade
Gain (Loss) on Sale of Investments
799.81,121-124.34-177.44--
Upgrade
Gain (Loss) on Sale of Assets
-232.44-9.3216.99-1,052-14.299.34
Upgrade
Asset Writedown
-27.61-36.72---44.82-2,267
Upgrade
Pretax Income
-7,2473,2031,9298,70219,22517,455
Upgrade
Income Tax Expense
-1,056-306.081,678-194.05-539.21-1,719
Upgrade
Net Income
-6,1913,509251.478,89619,76519,174
Upgrade
Net Income to Common
-6,1913,509251.478,89619,76519,174
Upgrade
Net Income Growth
-1295.23%-97.17%-54.99%3.08%481.02%
Upgrade
Shares Outstanding (Basic)
515151515151
Upgrade
Shares Outstanding (Diluted)
515151515151
Upgrade
Shares Change (YoY)
-0.33%-0.24%-0.76%0.05%0.00%-
Upgrade
EPS (Basic)
-122.3369.214.95173.74386.19374.67
Upgrade
EPS (Diluted)
-122.3369.214.95173.74386.19374.67
Upgrade
EPS Growth
-1298.63%-97.15%-55.01%3.08%481.02%
Upgrade
Free Cash Flow
21,57827,23122,434-3,766-1,63318,368
Upgrade
Free Cash Flow Per Share
426.37537.18441.48-73.55-31.91358.92
Upgrade
Gross Margin
51.10%55.62%56.25%59.29%57.08%57.80%
Upgrade
Operating Margin
-5.69%1.29%1.37%9.94%6.70%15.76%
Upgrade
Profit Margin
-4.75%2.60%0.23%8.76%22.31%17.68%
Upgrade
Free Cash Flow Margin
16.55%20.18%20.40%-3.71%-1.84%16.94%
Upgrade
EBITDA
-4,1624,9904,55812,8248,82919,805
Upgrade
EBITDA Margin
-3.19%3.70%4.14%12.62%9.97%18.26%
Upgrade
D&A For EBITDA
3,2603,2473,0532,7252,8942,715
Upgrade
EBIT
-7,4231,7431,50610,0995,93517,090
Upgrade
EBIT Margin
-5.69%1.29%1.37%9.94%6.70%15.76%
Upgrade
Effective Tax Rate
--86.97%---
Upgrade
Advertising Expenses
-3,2873,0902,1121,8891,579
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.